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Abstract
Background:  Application of plasmid DNA for immunization of food-producing animals
established new standards of food safety. The addition of foreign products e.g. pDNA into the food
chain should be carefully examined to ensure that neither livestock animals nor consumers develop
unpredicted or undesirable side-effects.
Methods: A quantitative real-time PCR (QRTPCR) methodology was developed to study the
biodistribution and persistence of plasmid DNA vaccine pDNAX (pVAX-Hsp60 TM814) in mice
and beef cattle. The linear quantification range and the sensitivity of the method was found to be
10 – 109 copies per reaction (500 ng/gDNA) and 3 copies per reaction, respectively.
Results: Persistence of pDNAX in mice muscle tissue was restricted to injection site and the
amount of pDNAX showed delivery formulation dependent (naked pDNA, electroporation,
cationic liposome complexes) and mouse age-dependent clearance form injection site but pDNAX
was still detectable even after 365 days. The QRTPCR analysis of various muscle tissue samples of
vaccinated beef bulls performed 242–292 days after the last revaccination proved that residual
pDNAX was found only in the injection site. The highest plasmid levels (up to 290 copies per
reaction) were detected in the pDNAX:CDAN/DOPE group similarly to mice model. No pDNA
was detected in the samples from distant muscles and draining lymph nodes.
Conclusion: Quantitative real-time PCR (QRTPCR) assay was developed to assess the residual
pDNA vaccine pVAX-Hsp60 TM814 in mice and beef cattle. In beef cattle, ultra low residual level
of pDNA vaccine was only found at the injection site. According to rough estimation, consumption
of muscles from the injection site represents almost an undetectable intake of pDNA (400 fg/g
muscle tissue) for consumers. Residual plasmid in native state will hardly be found at measurable
level following further meat processing. This study brings supportive data for animal and food safety
and hence for further approval of pDNA vaccine field trials.
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Background
DNA-based vaccines represent a new and rapidly progress-
ing area in vaccinology. So far, plasmid DNA (pDNA) vac-
cines have been reported to induce protective immunity
in numerous animal models of parasitic, viral and bacte-
rial diseases [1]. Moreover, pDNA vaccines appear to be
well tolerated and exhibit a minimal risk of in vivo
genome integration [2-8]. In addition, persistent plasmid
does not replicate inside the cells [7] and there are no sig-
nificant increases in anti-DNA antibodies leading to
autoimmune reactions [9]. Although preclinical studies
on animal models document overall safety, some issues
and potential risks related to food-producing animals
need to be addressed directly on target species since these
represent separate issues to clinical applications. Thus far,
data on the rates of clearance, or conversely persistence, of
pDNA post injection into animals is only limited, there-
fore potential risks must be extrapolated from model ani-
mal studies. Quantitative biodistribution studies have
been performed in mice [3-7,9-17], rats [18], rabbits
[2,8,9,13,19], sheep [20], dog [21] and macaques [22], all
post intramuscular (i.m.) administration of pDNA. Grati-
fyingly, all the studies have given evidence for overall
safety as well.
Quantitative real-time PCR (QRTPCR) is the most widely
used method for specific quantitative assay of ultra low
concentration of pDNA in biological materials. Such data
are necessary for the assessment of the risk of residual
plasmid presence in consumable parts of DNA vaccinated
livestock, mainly in muscles. Nowadays, there are no
definitive guidelines available to approve usage of DNA
vaccines in food- producing animals. In this work, the
QRTPCR method was used for the study of the persistence
of pDNA at the injection sites in mice and beef cattle. For
this reason we developed an isolation and detection QRT-
PCR based methodology for the accurate quantification of
residual levels of vaccine pDNAX (pVAX-Hsp60 TM814)
in the muscles after various approaches to vaccine appli-
cation (naked pDNA, pDNA with electroporation, pDNA
complexed with cationic liposomes). The primary motiva-
tion for this study was to obtain data for further negotia-
tions with the State Veterinary Authority (Czech Republic)
to get the approval for field trials with pDNAX against
ringworm (Trichophyton mentagrophytes)[23].
Materials and methods
Plasmids
The plasmid pDNAX (pVAX-Hsp60 TM814), encoding
the heat shock protein 60 (Hsp60) from Trichophyton men-
tagrophytes [24] and the plasmid pLacZ (pcDNA3.1/LacZ),
expressing β-galactosidase, were used in this study. The
plasmid DNA was produced in XL-1 Blue E. coli strain and
purified with Qiagen Giga prep kit (Qiagen, Germany) to
provide endotoxin free plasmid. Plasmid integrity was
confirmed by electrophoresis on 0.8% agarose gel. The UV
absorbance was used for quantification of DNA (A260)
and purity (A260/280) of plasmid preparation. The concen-
tration of stock plasmid preparation was 2 mg/ml, the
content of supercoil form was more than 90%, and the
A260/A280 was between 1.8–1.90.
Preparation of liposomes and pDNAX-liposome complex
Positively charged lipid N1-cholesteryloxycarbonyl-3,7-
diazanonan-1,9-diamine (CDAN) and neutral colipid
dioleoyl L-α-phosphatidylethanolamine (DOPE) in 1:1
molar ratio were used for preparation of liposomes. Fluo-
rescently labelled liposomes were prepared by addition of
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-lissa-
mine rhodamine B (PE-rd)(1 mol % of total lipids). Lip-
ids used in this study were purchased from Avanti Polar
Lipids, Inc., USA. The lipid mixture was dissolved in
freshly distilled chloroform and the solvent was evapo-
rated under reduced pressure using rotary evaporator
Laborota 4000 (Heidolph, Germany). Dry lipid film was
hydrated in 4 mM HEPES buffer pH 7.2. Monodisperse
liposomal preparation was obtained by extrusion through
100 nm Isopore filters (Millipore, Czech Republic). The
size distribution and the zeta potential of resulting lipo-
somes were measured using Zetasizer Nano ZS (Malvern,
UK). Complexes of pDNAX with liposomes were prepared
by incubation of the mixture of DNA with liposomes in
1:5 weight ratio at room temperature for 20 min [25].
pDNA application to mice
The vaccination experiments were approved by the Ethical
Committee of the Veterinary Research Institute, Brno,
Czech Republic.
Experiment I
BALB/c mice (7–8 weeks of age) were divided into one
control and three test groups. Various formulations of
pDNAX (naked pDNAX, naked pDNAX followed by elec-
troporation, liposomal complex pDNAX:CDAN/DOPE)
were applied by i.m. injection route. On day 0, the tested
animals received single injection into the right calf mus-
cle. In each experimental group, pDNAX (10 μg compris-
ing approximately 1012-1013 copies) in a total volume of
50 μl was applied. An electroporator (developed in the
laboratory of Prof. Yuhong Xu at Shanghai Jiao Tong Uni-
versity, Shanghai) was used in these experiments. Six elec-
tric pulses (duration 20 ms, field strength 150 V/cm, the
interval between the pulses 1 s, the gap distance between
electrodes 3 mm) were applied by two parallel needle
electrodes (distance of the needles was 3 mm) immedi-
ately after i.m. injection. Injection point was in the middle
between the electrodes. 50 μl of PBS were applied to mice
of the control group. The animals were kept under stand-
ard conditions during the whole experimental period.
Neither lost of weight nor pathological changes in theGenetic Vaccines and Therapy 2008, 6:11 http://www.gvt-journal.com/content/6/1/11
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skin, somatomotoric activity or behaviour pattern were
observed. At the end of each experimental period i.e.: 1, 7,
28, 90, 180 and 365 days after administration, 4 animals
from each test group and 2 animals from the control
group were sacrificed. Both quadriceps muscles from each
mouse were collected for the evaluation of the persistence
of pDNAX. The samples of muscles were homogenised,
weighted, frozen in liquid nitrogen and stored at -70°C
until further processing.
Experiment II
The influence of the age of the mice on the dynamics of
plasmid clearance during 1 month period after adminis-
tration was tested on BALB/c mice 5 weeks of age. Experi-
mental design was the same as in Experiment I.
Experiment III – fluorescent liposomes and analysis of gene 
expression
Single dose of pLacZ (10 μg) was injected into calf muscle
of BALB/c mice (5 weeks of age). Plasmid pLacZ was deliv-
ered in the following forms: naked DNA, naked DNA fol-
lowed by electroporation, and pDNA complexed with
fluorescent cationic liposomes (CDAN/DOPE/PE-rd).
The samples of muscles were taken at the day 1, 7, 14 and
28 after the administration. Tissue sections of the thick-
ness 7 μm were prepared by cryocat Leica CM1900 (Leica,
Germany) and stained for β-galactosidase expression
using the substrate X-gal (Sigma, Czech Republic). The
distribution and persistence of fluorescently labelled
pDNA:(CDAN/DOPE/PE-rd) complexes were evaluated
using fluorescence microscope Eclipse TM200 with CCD
camera (Nikon, Japan) and the images were recorded
using Lucia software (Laboratory Imaging Ltd., Czech
Republic).
pDNA application to beef cattle
The vaccination experiment was approved by the Ethical
Committee of the Veterinary Research Institute, Brno and
University of Palacky, Medicinal Faculty, Olomouc. Ten
beef cattle bulls (3 months of age) were divided into three
experimental groups. In each experimental group, pDNAX
(500 μg per dose; this dose was found to be sufficient for
induction of the immune response in calves [23]) in vari-
ous formulations (naked pDNAX, pDNAX in combina-
tion with liposomal adjuvant B30-norAbu-MDP
(lipophilic derivative of muramyl dipeptide entrapped
into liposomes; this compound was synthetised at the
Institute of Organic Chemistry and Biochemistry, Prague),
complex pDNAX:CDAN/DOPE) was administered by i.m.
single needle injection into right coccygeus muscle. The
animals were re-vaccinated after three weeks by the same
dose, formulation, and procedure. The bulls were slaugh-
tered 242–292 days after the second vaccination and
whole right coccygeus muscle (injection site), whole left
coccygeus muscle (opposite-to-injection site), random tis-
sue samples from gluteus muscle (distant muscle tissue),
and poplitheal lymph nodes were collected. The samples
of muscles were cut into small pieces, homogenised by
blender and stored at -70°C before further processing.
Various numbers of samples from particular tissues were
prepared and taken for analyses: injection site (n = 5),
opposite-to-injection site (n = 4), distant muscle tissue (n
= 3), each draining lymph node (n = 2).
DNA extraction from tissue sample
The isolation of genomic DNA (gDNA) from the samples
of tissue taken from mice or beef cattle was performed by
modification of guanidine thiocyanate (GuSCN) lysis
method followed by binding of DNA to SiO2 [26]. The
average weights of mice muscle samples and the samples
from beef cattle muscles were 100–150 mg and 200 mg,
respectively. The samples were mixed in 2-ml tubes with 1
ml of lysis buffer (5 M GuSCN; 0.05 M Tris-HCL, pH 6.4;
0.02 M EDTA, pH 8.0; 1.3% Triton X-100) and about 10
pcs. of 2.5 mm glass beads. The mixture was homogenised
twice in Magnalyser (Roche, Germany) for 30 s at 6000
rpm. Then the suspension was centrifuged (14000 g, 10
min.); 1 ml of the supernatant from mice tissue samples
or 700 μl of the supernatant from beef cattle tissue sam-
ples was transferred in 1.5 ml tube, filled with lysis buffer
to the total volume of 1.2 ml, and then 50 μl of silica sus-
pension (freshly prepared on the preceding day by mixing
100 mg of Celite with 500 μl of water and 5 μl of 32%
HCl) was added. The tubes were vortexed for 30 s. The
mixture was incubated at room temperature for 10 min.,
centrifuged (14000 g, 1 min.), and the supernatant was
discarded. The silica pellet was washed twice with 1 ml of
washing buffer (5 M GuSCN; 0.05 M Tris-HCL, pH 6.4;
0.02 M EDTA, pH 8.0), twice with 1 ml of 70% ethanol,
and once with 1 ml of acetone. Subsequently, silica pellet
was dried in heated block at 56°C for 15 min, followed by
extraction step performed twice: mixing with 80 μl of tem-
pered (56°C) TE-buffer (10 mM Tris-HCl, 1 mM EDTA
pH 8.0), incubation in heated block for 10 min., and cen-
trifugation (14000 g, 1 min.). 80 μl of the recovered
supernatant was transferred into clean tube, centrifuged
again (14000 g, 1 min.), and used for QRTPCR analysis.
20-μl volumes were taken from each extracted DNA sam-
ple to measure DNA concentration (A260), purity (A260/
A280), and integrity (0.6% agarose gel electrophoresis).
QRTPCR analysis
The Genecompare software (Applied-Maths, Belgium)
was used to design primers amplifying a sequence stretch
that contains plasmid specific promoter sequence (CMV)
as well as sequence from hsp60 gene, generating 161 bp
specific product. 500 ng of genomic DNA (gDNA) tem-
plate was amplified in duplicate in glass capillaries in a
final volume of 20 μl using 2× Real time PCR Syber green
master mix (Qiagen, Germany) with 0.5 μM primers:Genetic Vaccines and Therapy 2008, 6:11 http://www.gvt-journal.com/content/6/1/11
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CMV-Hsp60-F: 5'-ACTATAGGGAGACCCAAGCT-3' CMV-
Hsp60 R: 5'-GCCTGTAGGTACTCGACAAC-3' Optimal
PCR cycling conditions were: 15 min. pre-incubation at
95°C, 45 amplification cycles consisting of denaturation
at 95°C for 10 s, annealing at 61°C for 25 s, extension at
72°C for 10 s and data acquisition at 78°C for 1 s using a
temperature transition rate of 20°C/s in the LightCycler
1.5 instrument (Roche, Germany). Second derivative
maximum method was used for Ct calculation from
amplification curves. The amount of pDNAX in the tested
samples was calculated by the comparison of the sample's
Ct value with Ct values of the titration curve of genomic
samples artificially spiked with pDNAX. The results for
each mouse group were recalculated and are expressed as
mean plasmid copy number per μg of gDNA (PCN/μg
gDNA).
Precautions to prevent contamination
All the manipulations with stock plasmid, tissue sam-
pling, QRTPCR set up and template addition were done in
separated working areas [27]. To prevent cross-contami-
nation, the non-treated animals were handled before the
vaccinated animals. Samples from the vaccinated animals
were processed in the following manner: distant muscle
tissues (beef cattle), muscle tissue from opposite-to-injec-
tion site (mice: left calf muscle, beef cattle: left coccygeus
muscle), injection site (mice: right calf muscle, beef cattle:
right coccygeus muscle). Disposable materials were used
whenever possible. The work surfaces and equipment
were decontaminated by either 10% bleach or DNAoff
(Fluka, Germany).
Results
Validation of QRTPCR method
Persistence of pDNAX was determined by a QRTPCR
methodology designed to specifically recognize the
stretch of promoter-insert from the pDNAX plasmid. The
methodology was initially investigated for sensitivity, spe-
cificity and linearity, in the detection of pDNAX plasmid.
Firstly, the detection method was studied as part of the
protocol for isolation of genomic DNA (gDNA) from
mouse and beef muscle tissue. This protocol for isolation
was found to be scalable up to 200 mg of muscle tissue,
and in repeated applications of the QRTPCR methodol-
ogy no inhibition due to sample matrix or presence of
inhibitors was observed. Thereafter, pDNAX was intro-
duced to gDNA allowing the detection limit (DL) and lin-
ear quantification range (LQL) of the QRTPCR
methodology to be determined. In this instance, the LQL
was found to be within the range of 40-4 × 109 ag (10-1 ×
109 PCN/500 ng gDNA and the DL was shown to be 10 ag
(3 PCN/500 ng gDNA) (Fig. 1). Finally, mouse and beef
Linearity analysis after QRTPCR amplification Figure 1
Linearity analysis after QRTPCR amplification. Dilution series of pDNAX (109 – 3 × 10°copies) was amplified with 500 
ng of mouse gDNA. Full squares represent Cp values (crossing point) recorded from three independent pDNAX dilutions. The 
strait line represents linear regression analysis with correlation coefficient (R2) greater than 0,99.Genetic Vaccines and Therapy 2008, 6:11 http://www.gvt-journal.com/content/6/1/11
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muscle tissue samples were spiked with quantities of
pDNAX in the range from 10-4 × 109 ag. Thereafter, com-
plete pDNAX isolation procedures were performed dem-
onstrating that pDNA recovery was in the range of 65–
95%. The detection limit of pDNAX isolation from tissue
samples was found to be 800 ag (100 PCN/500 ng
gDNA). This parameter represents the lowest amount of
pDNAX that could be detected in all replicates of spiked
samples by QRTPCR.
Biodistribution and persistence in mice
Experiment I
The pDNAX plasmid (10 μg) was injected i.m. to 8-week-
old mice and then detectable levels of plasmid were
assayed as a function of time by QRTPCR. As shown (Fig.
2), pDNAX introduced i.m. to 8-week-old mice persisted
at detectable levels in the region of the injection site for up
to one year after administration regardless of the plasmid
formulation and method of application. However, rates of
clearance of pDNAX varied with the mode of administra-
tion. One day post injection, pDNAX remaining in muscle
samples from three different groups was in the following
order: pDNAX:CDAN/DOPE: 374 ng/μg gDNA (4.60 ×
107 PCN/500 ng gDNA) > pDNAX electroporation: 2600
pg/μg gDNA (3.20 × 105 PCN/500 ng gDNA) > naked
pDNAX: 689 pg/μg gDNA (1.70 × 105  PCN/500 ng
gDNA). In the first group, pDNAX was injected in com-
plex with CDAN/DOPE cationic liposomes; in the second
group, pDNAX was injected with electroporation; in the
third group naked pDNAX was injected alone. Thereafter,
in the case of the pDNAX:CDAN/DOPE group levels of
pDNAX were found to undergo a 10-fold decline between
the day 7 and the day 28, followed by a further 100-fold
decline by the day 90, so that by the day 365 a detectable
level of only 535 ag/μg gDNA (1.35 × 102 PCN/500 ng
gDNA) was determined by QRTPCR (Fig. 2). By contrast,
in the case of both pDNAX electroporation and naked
pDNAX groups, clearance rates were more considerable.
In the case of the naked DNAX group, final plasmid levels
were found to be below the quantification limit of 40 ag/
μg gDNA (10 PCN/500 ng gDNA (Fig. 2).
Experiment II
Identical experiment was performed with 5-week-old
mice to evaluate a possible relationship between the ani-
mal age and the rate of clearance of pDNAX from the site
Levels of pDNAX detected by QRTPCR in calf muscle (at the injection site) after administration of 10 μg pDNAX in 8-week  old BalB/C mice Figure 2
Levels of pDNAX detected by QRTPCR in calf muscle (at the injection site) after administration of 10 μg 
pDNAX in 8-week old BalB/C mice. The line connects the average levels of plasmid DNA detected by QRT-PCR in 500 
ng of isolated DNA (MC/r) ± SD (four mice per time point). The straight line represents quantification limit of QRTPCR assay 
(10 pDNAX copies/reaction). The dotted line represent detection limit of QRTPCR assay (3 pDNAX copies/reaction). The 
data from control group were omitted (all control animals were negative). Routes of application: full circle denotes naked 
pDNAX; full triangle denotes pDNAX plus electroporation; full square denotes pDNAX:CDAN-DOPE complex.Genetic Vaccines and Therapy 2008, 6:11 http://www.gvt-journal.com/content/6/1/11
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of injection. In both cases, naked pDNAX and pDNAX
electroporation groups, the rates of clearance of pDNAX
were found to be slower for 5-week-old mice in compari-
son to the corresponding situation in 8-week-old mice
(compare Fig. 2 and Fig. 3). Nevertheless, the final differ-
ences in pDNAX levels between pDNAX:CDAN/DOPE
and the pDNAX electroporation groups were still in the
range of 100-fold, with an even greater gap of over 104-
fold between pDNAX:CDAN/DOPE and naked pDNAX
groups. In this instance too, a difference of 1–2 orders of
magnitude also existed between the measured plasmid
levels in the pDNAX electroporation group and the naked
pDNAX group at all time points analyzed (Fig. 3), in par-
tial contrast to our observations with 8-week animals (Fig.
2).
Experiment III- analysis of gene expression and distribution of 
fluorescent complex of pDNA/cationic liposomes
Flourescently labelled pDNAX:CDAN/DOPE complexes
were prepared and injected i.m. into 5-week old mice in
order to make comparison with the QRTPCR data (Fig. 3).
Post administration, complexes were clearly visible, local-
ised at the site of application, and persisted for more than
four weeks as shown in histological sections by fluores-
cent microscopy (Fig. 4). This is in a good correlation with
the persistence of pDNAX as determined by QRTPCR (Fig.
3). Similar data were found in the group of 8-week-old
mice (data not shown). Transfection experiments were
then performed by the administration of naked pLacZ
injected i.m. into 5-week and 8-week old mice. Histologi-
cal analyses of muscle tissue sections revealed that β-galac-
tosidase expression was undetectable after the injection to
8-week old mice with naked pLacZ (10 μg) (data not
shown). However, when pLacZ (10 μg) was introduced
together with electroporation pulse, transfection was
detectable, but only a few myocytes were found to be pos-
itive for β-galactosidase expression. In contrast, β-galac-
tosidase expression was much more evident with 5-week
old mice. Myocyte bundles expressing β-galactosidase
were clearly localised around the site of injection and
there was little tissue damage associated with electropora-
tion. Several β-galactosidase positive myocytes were
Levels of pDNAX detected by QRTPCR in calf muscle (at the injection site) after administration of 10 μg pDNAX in 5-week  old BalB/C mice Figure 3
Levels of pDNAX detected by QRTPCR in calf muscle (at the injection site) after administration of 10 μg 
pDNAX in 5-week old BalB/C mice. The line connects the average levels of plasmid DNA expressed in logarithm scale 
detected by QRTPCR in 500 ng of isolated DNA (MC/r) ± SD (four mice per time point). The straight line represent quantifi-
cation limit of QRTPCR assay (10 pDNAX copies/reaction). The dotted line represent detection limit of QRTPCR assay (3 
pDNAX copies/reaction). The data from control group were omitted (all control animals were negative). Routes of applica-
tion: full circle denotes naked pDNAX; full triangle denotes pDNAX plus electroporation; full square denotes pDNAX:CDAN-
DOPE complex.Genetic Vaccines and Therapy 2008, 6:11 http://www.gvt-journal.com/content/6/1/11
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found also four weeks after electroporation. Micrographs
of the tissue sections documenting β-galactosidase expres-
sion are presented (Fig. 4).
Biodistribution and persistence in beef cattle
Residual pDNAX levels in various samples of tissues taken
from beef cattle slaughtered 9 months after application of
plasmid are summarized (Table 1). QRTPCR examina-
tions of muscle tissue taken from the injection site
revealed very low residual or nearly zero pDNAX levels in
all animals tested. Plasmid levels detected in animals
injected with naked pDNAX group were predominantly
below quantification 40 ag/μg gDNA (10 PCN/500 ng
gDNA) or detection 13 ag/μg gDNA (3 PCN/500 ng
gDNA) limit. Slightly higher residual plasmid levels, but
mostly close to quantification limit, were also detected in
the cases where pDNAX was injected with a liposomal for-
mulation of adjuvant B30-norAbu-MDP. The highest lev-
els of retention (288 PCN/500 ng gDNA) were recorded at
the injection site in the muscle samples from beef cattle
injected with pDNAX:CDAN/DOPE. However, plasmid
levels from all slaughtered animals showed progressive
decreases in pDNAX levels below the quantification limit
after longer time periods. Gratifyingly, essentially no plas-
mid was found at either distant muscle tissue or in drain-
ing lymph node samples. Muscle samples from opposite-
to-injection site (internal negative control) were also neg-
ative for the presence of pDNAX.
Expression of β-galactosidase activity and persistence of fluorescent liposome- pLacZ complexes in mice calf muscles Figure 4
Expression of β-galactosidase activity and persistence of fluorescent liposome- pLacZ complexes in mice calf 
muscles. Mice calf muscles were histochemically stained for β-galactosidase activity at the day 1 (A) and at the day 28 (B) after 
i.m. injection of 10 μg pLacZ followed by electroporation. Histological detection of fluorescent liposome-pDNA complex (10 
μg pLacZ/CDAN:PE-rh) in mice calf muscles at the day 1 (C) and 28 (D) after administration into young mice (the age of 5 
weeks).Genetic Vaccines and Therapy 2008, 6:11 http://www.gvt-journal.com/content/6/1/11
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General safety
After the injection of pDNAX (or pLacZ), both mice and
cows from all the tested groups survived throughout the
duration of the experiments and neither any apparent
pathological changes at the site of injection nor loss of
body weight were observed indicating that pDNAX
(pVAX-Hsp60 TM814) vaccine and its formulations as a
complex with cationic liposomes or liposomal adjuvant
B30-norAbu-MDP were well tolerated in both species.
Application of electroporation with or without previous
local or general anesthesia did not lead to any changes of
somatomotoric activity or even paraplegia in mice.
Discussion
Limited data on the examination of the effect of pDNA
vaccines on food-producing animals have been reported
so far and we can only extrapolate the results obtained in
the model animals. Different regulation acts on geneti-
cally modified organisms and their interpretation by
national authorities represent serious obstacles for the
field of DNA vaccination experiments on large animals.
DNA vaccines have not yet been licensed in many coun-
tries, therefore national authorities are not experienced
with this kind of product and do not differentiate between
gene medication and gene modification. Within the EU,
two opposite points of view are maintained as regards
DNA vaccinated animals. The first one, held by The British
Agriculture and Environment Biotechnology Committee,
does not consider DNA vaccinated animals as genetically
modified ones due to the low risk of insertion of pDNA
into genome. The second one, held by The Norwegian
Directorate for Nature Management, states that DNA vac-
cinated animals should be considered as genetically mod-
ified for as long as the added DNA is present. In other
words, gene medication is the subset of gene modification
[28]. The safety concerns raised by the use of plasmid
DNA for immunization of food producing animals, live-
stock and poultry are obviously distinct from those in
humans. The addition of foreign products e.g. pDNA into
the food chain should be carefully considered to ensure
that neither livestock animals nor consumers develop
unpredicted or undesirable side-effects. While the safety
of DNA vaccines was documented in animal and human
trials, the problem of residual plasmid in consumable
parts of livestock and poultry has not yet been solved on
the level of the State Veterinary Authority and regulatory
veterinarians. In contrast to experiments performed on
small rodents, vaccination field trials on large animals,
Table 1: Effect of various pDNAX formulations on its persistence in beef cattle after i.m. administration
Beef cattle groups Beef cattle ID 
code
Interval between 
2nd immunisation 
and slaughter 
(days)
pDNA copies at 
the injection site/
500 μg DNA 
(n = 5)
pDNA copies 
opposite -to- 
injection site 
muscle (n = 4)
pDNA copies 
distant muscle 
(n = 3)
pDNA copies 
DLNa total (n = 6)
pDNA 20087 242 < LQL (2); < DL 
(2); Neg. (1)
0/4 0/3 0/6
20105 277 73.97; 35.59; < 
LQL (2); < DL (1)
0/4 0/3 0/6
20080 284 < LQL (5) 0/4 0/3 0/6
DNA + B30-Nor-
AbuMDP
20083 242 19.86; 16.23; 15.5; 
< LQL (2)
0/4 0/3 0/6
28504 270 92.78; 29.25; 
28;92; 24.04; 23.75
0/4 0/3 0/6
20090 291 13.48; 12.73; 
10.87; < LQL (1); 
Neg. (1)
< DL(1/4) 0/3 0/6
DNA:cationic 
liposome complex
20086 270 288; 220.08; 
200.60; 30.07; < 
LQL (1)
0/4 0/3 0/6
20089 277 228.9; 169.90, 
134.70; 39.57; 
39.00
0/4 0/3 0/6
3654 291 149.3; 64.79; 
46.60; 18.88; 18.73
0/4 0/3 0/6
20081 298 < LQL (5) 0/4 0/3 0/6
The total amount 1000 μg of pDNAX in two equal doses was delivered into coccygeus muscle (injection site) as naked pDNAX, naked pDNAX + 
liposomal B30-norAbuMDP, and cationic liposome complex pDNAX:CDAN-DOPE. The level of pDNAX in the injection site, opposite-to-injection 
site, distant muscle tissues and draining lymph nodes was examined after 242–298 days after the second immunisation. Plasmid copies are 
expressed as mean plasmid copies per 500 ng of genomic DNA (MC/r) from duplicate QRTPCR assay. < LQL: below linear limit of quantification 
(10 copies/reaction), < DL: below detection limit (3 copies/reaction), Neg.: negative sample, aDLN- draining lymph nodes.Genetic Vaccines and Therapy 2008, 6:11 http://www.gvt-journal.com/content/6/1/11
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e.g. cows, are more expensive and are subjected to more
strict regulations.
The condemnation of whole animals and the processing
of their cadavers in rendering plants pose not only an eco-
nomic problem but also an ethic one. The presented study
has shown that pVAX-Hsp60 TM814 vaccine and its for-
mulations as a complex with cationic liposomes or lipo-
somal adjuvant B30-norAbu-MDP were well tolerated by
both species. From the practical point of view, the regula-
tory authorities will demand a reliable, sensitive and cost
effective method for the determination of the amount of
residual plasmid and its localization in the body at the
time of the slaughter. The detection method based on
QRTPCR was proved to be suitable for the exact quantifi-
cation of residual plasmid levels in muscle tissues after
i.m. application of pDNA vaccine. By the use of the artifi-
cially spiked muscle tissue samples we documented, that
pDNA was efficiently recovered (65–95% of the initial
amount) within the wide range of plasmid concentrations
that might occur in real tested samples (Fig. 1). The qual-
ity of the isolated DNA was sufficient for the development
of QRTPCR assay providing parameters ensuring high spe-
cificity, sensitivity and reproducibility for the precise
pDNA quantification. The sensitivity of our assay was
comparable to that published by Tuomela for the pDNA
GTU®-MultiHIV [18].
Biodistribution and persistence of pDNA in mice
Model studies on rodents covering overall biodistribution
and safety features are required before DNA vaccines enter
human clinical trials [29]. We used mouse model to pro-
vide information about plasmid clearance kinetics, which
is useful for further extrapolation for beef cattle. Biodistri-
bution studies, primarily those performed with naked
pDNA applied i.m., show that pDNA is completely
cleared from the injection site within 28 days or even
sooner. However, long-term persistence was reported as
well – by qualitative PCR: 18 wks [11], 180 days [7], 19
months [10], and 2 years [16] after application.
Our results confirm the previous observations that plas-
mid DNA is rapidly cleared from the injection site
[15,17,30]. Depending on the type of application, the
amount of pDNA found in mice after 24 hours in electro-
porated and naked group was less than 0.1% and less than
0.01%, respectively. Naked pDNA is immediately sub-
jected to degradation, therefore only limited fraction of
the applied plasmid is capable to reach the zone where
pDNA is protected (i.e. structures like T-tubules and cave-
olae [31]), against the attack of serum and tissue specific
nucleases [32].
Application of electroporation pulse leads to transient
membrane disruption facilitating pDNA uptake. Gener-
ally, electroporation improves pDNA uptake and leads to
several orders higher expression levels, as reviewed in
[33]. However, for further optimization of electropora-
tion parameters for clinical application it is necessary to
reduce a pain and potential muscle damage caused by this
technique [34-36]. The study published by Wang et al.
[37] determined, that critical parameters influencing elec-
troporation are plasmid concentration, injection volume,
concentration of saline media, size of plasmid DNA,
repeated gene transfer. However, neither the influence of
lag time between plasmid injection and electroporation
nor the effect of the age of mice was observed. On the con-
trary, we detected the age-dependent differences (5-week
old mice vs. 8-week old mice, Fig. 2 vs. Fig. 3) of residual
plasmid in muscles of mice vaccinated by naked pDNA or
electroporated. This could be explained by the age-
dependent changes of extracellular matrix structure,
which might affect the permeation of pDNA and hence
the efficiency of electroporation resulting in the decreased
transfection efficacy in the older mice [38]. This consider-
ation is also confirmed by our data obtained with 5-week
old mice, where the differences between the naked DNA
and the electroporated group were more clearly pro-
nounced (Fig. 3) and a slower clearance rate within the
first 28 days was observed (compare Fig. 2 and Fig. 3).
Such important effect of extracellular matrix on local
pDNA delivery was documented using the enzyme
hyaluronidase that breaks down the components of extra-
cellular matrix [39-41]. Rapid plasmid decline in naked
and electroporated group within the first 28 days (Fig. 2)
could be also related to transfection of other cells than
myocytes, e.g. endothelial cells, in which plasmid DNA is
unstable and could be lost during mitosis. Relative stabil-
ity of low plasmid level in muscle was observed within the
period of the day 28 and 1 year after administration.
pDNA is supposed to be located in the nucleus of myo-
cytes, which can retain pDNA for a long time. Gradual
decline of pDNA concentration could be explained by
normal myonuclei turn-over in myocytes [42]. For the
exact evaluation, whether the plasmid is integrated into
genomic DNA or presented in extrachromosomal state, a
precise gel purification method would be necessary
[4,5,12,13]. Furthermore, plasmid integration into
genomic DNA is a very rare event, usually lower than the
level of spontaneous mutation [4]. Wang et al. [5]
reported that less than 0.2% of the intracellulary pre-
sented pDNA was integrated into genomic DNA after
application of naked and electroporated plasmid, respec-
tively. According to such calculations, plasmid integration
into genomic DNA in our experiments would be mostly at
the level below quantification limit or even undetectable.
Cationic liposomes are mostly used as carries for intrave-
nous systemic delivery, but novel lipid combinations
might be suitable for i.m. delivery [2,43,44] and they haveGenetic Vaccines and Therapy 2008, 6:11 http://www.gvt-journal.com/content/6/1/11
Page 10 of 11
(page number not for citation purposes)
been found to be well tolerated in both, animals and
humans [45]. When we compared the cationic liposomes
with the standard method of i.m. delivery, i.e. the injec-
tion of naked pDNA without or with electroporation,
plasmid levels retained in mouse muscles after 24 hours
from pDNA:CDAN-DOPE group were even 100–1000×
higher (between 7–11% of the initial amount). Generally,
our data demonstrated a slower clearance of pDNA from
the injection site of pDNA:CDAN-DOPE group within the
period of day 1 and day 28 in comparison to both, the
naked and electroporated groups (Fig. 2 and Fig. 3). This
data would support the consideration that pDNA in lipo-
somal complex is more protected against the attack of
nuclease. With regards to the observation of Hartikka et
al[43], who noticed that another cationic lipid formula-
tion – Vaxfectin did not appear to increase transfection,
we can suppose that high plasmid levels are located extra-
cellulary. Using fluorescently labelled liposomes, histo-
logical analysis revealed that liposomal complexes were
mostly distributed along the injection lane, forming a
depot within muscle tissues even after 28 days (Fig. 4).
Biodistribution and persistence of pDNA in beef cattle
In order to facilitate further plasmid detection and poten-
tially minimise a condemnation of whole consumable
parts, coccygeus muscle was chosen as a suitable site for
immunization. It is important to note that this small mus-
cle, located closely to the root of the tail, is easy to reach
and remove after slaughter. Having 10 animals available
in experimental herd, we tested i.m. administration of
pDNA vaccine and its various formulations intended for
field vaccination trials. Unfortunately, we had not suitable
electrodes for the electroporation of larger animals at the
time of the experiments. Instead of electroporation we
applied pDNA vaccine in combination with liposomal
adjuvant B30-norAbu-MDP, which was proved to be
effective in guinea pigs immunized by the same pDNA
vaccine (unpublished results). Altogether, the performed
QRTPCR assay revealed that pDNA persisted in ultra-low
level at the injection site even 292 days after the second
administration of pDNA. The highest amount of pDNA
was detected in the group vaccinated by pDNA:cationic
liposome complexes. These data are in good accordance
with the results obtained in mice. The values of residual
pDNA in the group injected by naked pDNA were mainly
non-quantifiable. Combination of naked pDNA with the
liposomal adjuvant B30-norAbu-MDP resulted in levels
of residual pDNA close to quantification limit. It is impor-
tant to emphasize that no plasmid was detected in distant
muscle tissue, in draining lymph node or in the opposite
muscle directly connected with these lymph nodes. The
tissues located contralaterally to the injection sites could
also be considered as negative controls for each vaccinated
animal.
Conclusion
Quantitative real-time PCR (QRTPCR) assay was devel-
oped to assess a residual pDNA vaccine pVAX-Hsp60
TM814 in mice and beef cattle. In beef cattle, ultra low
residual level of pDNA vaccine was found only at the site
of injection. According to rough estimation, consumption
of muscles from the injection site represents almost an
undetectable income of pDNA (400 fg/g muscle tissue)
for the consumers. Residual plasmid in native state will
hardly be found at measurable level following further
meat. This study brings supportive data for animal and
food safety and hence for further approval of pDNA vac-
cine field trials.
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